NeuroSigma (Los Angeles), a company with a focus on neurotechnology, reported positive Phase II Clinical study results for the use of external Trigeminal Nerve Stimulation (eTNS) for the treatment of drug-resistant epilepsy. Results of the study were published online in the Jan. 30th issue of Neurology, the medical journal of the American Academy of Neurology (Minneapolis). Read More
